Explore the latest in prostate cancer, including recent screening guidelines and advances in management of localized and metastatic disease.
This narrative review describes the parallels and differences between prostate cancer and thyroid cancer regarding screening, diagnosis, risk stratification, and considerations for active surveillance.
This Viewpoint addresses whether there is sufficient evidence to support routine use of multiparametric magnetic resonance imaging as an adjunctive test for men with elevated prostate-specific antigen level and considers the practical implications of its widespread implementation.
This Viewpoint uses results of randomized clinical trials to explore whether the use of abiraterone acetate plus prednisone is a cost-effective and appropriate treatment option for patients with nonmetastatic castration-resistant prostate cancer.
This cohort study investigates whether treatment of Gleason score 9-10 prostate cancer with radical prostatectomy, adjuvant external beam radiotherapy, and androgen deprivation therapy (termed MaxRP) vs external beam radiotherapy, brachytherapy, and androgen deprivation therapy (termed MaxRT) was associated with prostate cancer–specific mortality and all-cause mortality risk.
This cohort study examines the association of androgen deprivation therapy with dementia in male veterans with prostate cancer who receive definitive radiotherapy.
This phase 2 clinical trial investigates the safety and efficacy of BIND-014, a docetaxel-containing nanoparticle targeting prostate-specific membrane antigen, for treating patients with metastatic castration-resistant prostate cancer.
This meta-analysis examines the association of Gleason grade with the effectiveness of androgen deprivation therapy with radiotherapy in treating patients with high-risk prostate cancer.
This large cohort study uses the SEER-Medicare database to evaluate the Medicare costs associated with diagnosis and treatment of nonmetastatic prostate cancer in men 70 years or older.
This cohort study examines whether an assay for the nuclear-localized androgen receptor splice variant 7 protein in circulating tumor cells can be used to estimate overall survival among patients with metastatic castration-resistant prostate cancer treated with taxanes vs androgen receptor signaling inhibitors.
This cohort study compares receipt of National Comprehensive Cancer Network (NCCN) guideline–discordant prostate cancer imaging (radionuclide, CT, or MRI) to stage incident prostate cancer among men being treated in the Veterans Health Administration system vs those receiving Medicare-covered services vs a combination of the two.
This systematic review and meta-analysis examines the association of smoking status with biochemical recurrence, metastasis, and cancer-specific mortality among patients with localized prostate cancer undergoing primary radical prostatectomy or radiotherapy.
This secondary analysis of a randomized clinical trial assesses the automated Bone Scan Index as an independent prognostic determinant of overall survival in men with metastatic castration-resistant prostate cancer.
This randomized clinical trial assesses whether dose-escalated radiation therapy vs standard dose improves survival for men with intermediate-risk prostate cancer.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: